ŠIMČÍKOVÁ, Daniela, Jana IVANČINOVÁ, Miroslav VEITH, Jaroslava DUSOVÁ, Veronika MATUŠKOVÁ, Jan NĚMČANSKÝ, Přemysl KUNČICKÝ, Oldřich CHRAPEK, Naďa JIRÁSKOVÁ, Jan GOJDA and Petr HENEBERG. Serum autoantibodies against hexokinase 1 manifest secondary to diabetic macular edema onset. Diabetes Research and Clinical Practice. CLARE: ELSEVIER IRELAND LTD, 2024, vol. 212, June 2024, p. 1-9. ISSN 0168-8227. Available from: https://dx.doi.org/10.1016/j.diabres.2024.111721.
Other formats:   BibTeX LaTeX RIS
Basic information
Original name Serum autoantibodies against hexokinase 1 manifest secondary to diabetic macular edema onset
Authors ŠIMČÍKOVÁ, Daniela (203 Czech Republic), Jana IVANČINOVÁ (203 Czech Republic), Miroslav VEITH (203 Czech Republic), Jaroslava DUSOVÁ (203 Czech Republic), Veronika MATUŠKOVÁ (203 Czech Republic, belonging to the institution), Jan NĚMČANSKÝ (203 Czech Republic), Přemysl KUNČICKÝ (203 Czech Republic), Oldřich CHRAPEK (203 Czech Republic, belonging to the institution), Naďa JIRÁSKOVÁ (203 Czech Republic), Jan GOJDA (203 Czech Republic) and Petr HENEBERG (203 Czech Republic).
Edition Diabetes Research and Clinical Practice, CLARE, ELSEVIER IRELAND LTD, 2024, 0168-8227.
Other information
Original language English
Type of outcome Article in a journal
Field of Study 30207 Ophthalmology
Country of publisher Ireland
Confidentiality degree is not subject to a state or trade secret
WWW URL
Impact factor Impact factor: 5.100 in 2022
Organization unit Faculty of Medicine
Doi http://dx.doi.org/10.1016/j.diabres.2024.111721
UT WoS 001263613100001
Keywords in English Autoimmunity; Glycolysis; Disease marker; Disease prediction; Tissue damage; Vitreous fluid
Tags 14110219, rivok
Tags International impact, Reviewed
Changed by Changed by: Mgr. Tereza Miškechová, učo 341652. Changed: 5/8/2024 13:37.
Abstract
Aims Autoantibodies against hexokinase 1 (HK1) were recently proposed to be associated with diabetic macular edema (DME). We hypothesized that anti-HK1 autoantibodies can be used as DME markers and to predict DME onset. Materials and methods Serum from patients with 1) DME, 2) diabetes mellitus (DM), 3) allergies or autoimmunities, and 4) control subjects was tested for anti-HK1 and anti-hexokinase 2 (HK2) autoantibodies by immunoblotting. Patients with DM were prospectively followed for up to nine years, and the association of anti-HK1 antibodies with new-onset DME was evaluated. The vitreous humor was also tested for autoantibodies. Results Among patients with DME, 32 % were positive for anti-HK1 autoantibodies (42 % of those with underlying type 1 DM and 31 % of those with underlying type 2 DM), and 12 % were positive for anti-HK2 autoantibodies, with only partial overlap of these two groups of patients. Anti-HK1 positive were also 7 % of patients with DM, 6 % of patients with allergies and autoimmunities, and 3 % of control subjects. The latter three groups were anti-HK2 negative. Only one of seven patients with DM who were initially anti-HK1 positive developed DME. Conclusions Anti-HK1 autoantibodies can be used as DME markers but fail to predict DME onset.
PrintDisplayed: 21/8/2024 09:21